Clinical trials: Masked Hypertension
Ocular Hypertension, Glaucoma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma.
- Trial name
- NCT01033422
- Testing
- CF101
- Where
- 3 sites in Bulgaria, Israel
- Volunteers
- 89 people
- Sponsor
- Can-Fite BioPharma
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Raised Intraocular Pressure
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
- Trial name
- NCT01173471
- Testing
- AZD4017
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Glaucoma
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
- Trial name
- NCT00716859
- Testing
- Timolol, latanoprost
- Where
- 48 sites in United States, Belgium and 18 more
- Volunteers
- 139 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
The Investigators will compare, in a randomized, prospective, masked and controlled fashion the effect of a non-steroidal anti-inflammatory agent (Acular LS), a corticosteroid (Pred Forte) and a placebo (Refresh Tears) on patient…
- Trial name
- NCT00478036
- Testing
- Acular LS, Pred Forte, Refresh Tears
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Open-Angle Glaucoma, Ocular Hypertension
Travoprost 3-Month Safety and Efficacy Study
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01453855
- Testing
- Travoprost ophthalmic solution, 0.003%, Travoprost ophthalmic solution, 0.004%
- Volunteers
- 1,099 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-Angle Glaucoma
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
- Trial name
- NCT02743780
- Testing
- MGV354 ophthalmic suspension
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Intraocular Pressure
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to…
- Trial name
- Voyager (NCT01223378)
- Testing
- BOL-303259-X, Latanoprost
- Where
- United States
- Volunteers
- 413 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04024072
- Testing
- Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Padagis LLC
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.
- Trial name
- NCT02558400
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
- Where
- United States
- Volunteers
- 718 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
- Trial name
- NCT03310580
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 40 sites in United States
- Volunteers
- 42 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691649
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 47 sites in United States
- Volunteers
- 426 people
- Sponsor
- Santen Inc.
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals